Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Depreciation and Depletion: 2009-2024

Historic Depreciation and Depletion for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Dec 2024 value amounting to $2.0 million.

  • Ironwood Pharmaceuticals' Depreciation and Depletion fell 6.31% to $475,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 6.48%. This contributed to the annual value of $2.0 million for FY2024, which is 27.68% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $2.0 million for FY2024, which was up 27.68% from $1.6 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Depreciation and Depletion registered a high of $3.6 million during FY2020, and its lowest value of $1.4 million during FY2022.
  • For the 3-year period, Ironwood Pharmaceuticals' Depreciation and Depletion averaged around $1.7 million, with its median value being $1.6 million (2023).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Depreciation and Depletion slumped by 57.27% in 2021, and later grew by 27.68% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Depreciation and Depletion (Yearly) stood at $3.6 million in 2020, then tumbled by 57.27% to $1.5 million in 2021, then dropped by 6.89% to $1.4 million in 2022, then climbed by 11.07% to $1.6 million in 2023, then climbed by 27.68% to $2.0 million in 2024.